| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (NCT01968213) | pharmaand GmbH | 2014-04-07 |
| Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients (NCT02490488) | AB Science | 2014-04-01 |
| Blood Collection From People With Ovarian Cancer (NCT02063464) | National Cancer Institute (NCI) | 2014-03-10 |
| Photoacoustic Imaging of the Ovary (NCT02110277) | UConn Health | 2014-03-01 |
| Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System (NCT04817501) | Tomsk National Research Medical Center of the Russian Academy of Sciences | 2014-02-14 |
| Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) (NCT02054351) | Ganymed Pharmaceuticals GmbH | 2014-02-06 |
| A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (NCT01991210) | Genentech, Inc. | 2014-02-06 |
| Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines (NCT03622931) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2014-02-01 |
| Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass (NCT02109367) | Southern Illinois University | 2014-02-01 |
| Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer (NCT02043158) | M.D. Anderson Cancer Center | 2014-01-16 |
| Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer (NCT02092363) | OncoMed Pharmaceuticals, Inc. | 2014-01-01 |
| Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin (NCT02017678) | Andrea McCart | 2014-01-01 |
| A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer (NCT02042885) | Otsuka Novel Products GmbH | 2014-01-01 |
| Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer (NCT02125513) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2014-01-01 |
| DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics (NCT02288676) | McGill University | 2014-01-01 |
| Ensuring Communication in Hospice by Oncology Study (ECHO) (NCT02069769) | Massachusetts General Hospital | 2014-01-01 |
| Regional Distribution Mapping of Lymph Node Metastasis in Epithelial Ovarian Cancer (NCT06853730) | Xu Huishan | 2014-01-01 |
| A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab (NCT01975831) | Ludwig Institute for Cancer Research | 2013-12-19 |
| A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors (NCT02033551) | AbbVie | 2013-12-01 |
| Predictive Clinical and Biological Parameters in Gynecological Cancer (NCT01977274) | Institut Paoli-Calmettes | 2013-12-01 |
| EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer (NCT02001272) | Hospices Civils de Lyon | 2013-12-01 |
| A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (NCT02009449) | Eli Lilly and Company | 2013-11-15 |
| EC17 for Intraoperative Imaging in Occult Ovarian Cancer (NCT02000778) | University of Pennsylvania | 2013-11-01 |
| Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer (NCT02132988) | Mackay Memorial Hospital | 2013-11-01 |
| The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (NCT01556841) | University College, London | 2013-11-01 |
| A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-11-01 |
| A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors (NCT02009631) | AbbVie | 2013-11-01 |
| Integrated Cancer Repository for Cancer Research (NCT02012699) | University of Nebraska | 2013-11-01 |
| Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma (NCT02039388) | Medical University of Vienna | 2013-11-01 |
| Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. (NCT01953107) | Sunnybrook Health Sciences Centre | 2013-11-01 |
| Tivozanib As Maintenance Therapy In GYN (NCT01972516) | Dana-Farber Cancer Institute | 2013-11-01 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (NCT01891344) | pharmaand GmbH | 2013-10-30 |
| Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion (NCT01997190) | Candel Therapeutics, Inc. | 2013-10-01 |
| Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer (NCT01936363) | EMD Serono | 2013-09-30 |
| Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (NCT02019524) | COL George Peoples, MD, FACS | 2013-09-30 |
| Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors (NCT01831089) | PharmaMar | 2013-09-01 |
| ONSD According to the Position During Laparoscopy (NCT01937104) | Chosun University Hospital | 2013-09-01 |
| Hula, a Physical Activity Intervention for Female-Cancer Survivors (NCT02351479) | University of Hawaii | 2013-09-01 |
| Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve (NCT01888159) | Karlstad Central Hospital | 2013-09-01 |
| LDE225 and Paclitaxel in Solid Tumors (NCT01954355) | Swiss Cancer Institute | 2013-09-01 |
| Assessment of Paclitaxel-Induced Neuropathy (NCT01953159) | University of Chicago | 2013-08-29 |
| A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer (NCT02093871) | ThermalCore Inc | 2013-08-01 |
| Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients (NCT01905163) | Centre Jean Perrin | 2013-08-01 |
| Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer (NCT01881451) | British Columbia Cancer Agency | 2013-08-01 |
| Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer (NCT01889615) | Odense University Hospital | 2013-08-01 |
| CT Antigen TCR-redirected T Cells for Ovarian Cancer. (NCT01567891) | Adaptimmune | 2013-07-09 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| Phase I Trial of VS-6766 Alone and in Combination With Everolimus (NCT02407509) | Royal Marsden NHS Foundation Trust | 2013-06-17 |
| An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1) (NCT01863693) | Hoffmann-La Roche | 2013-05-10 |
| Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families (NCT03119285) | University of Washington | 2013-04-01 |
| NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) (NCT03804866) | AGC Biologics S.p.A. | 2013-03-01 |
| An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer (NCT02151370) | Hoffmann-La Roche | 2013-03-01 |
| Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients (NCT01834469) | Jules Bordet Institute | 2013-03-01 |
| PET-CT vs. Integrated MR-PET Scanning of GYN Cancers (NCT01779128) | Massachusetts General Hospital | 2013-03-01 |
| Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer (NCT01826227) | Memorial Sloan Kettering Cancer Center | 2013-03-01 |
| Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer (NCT01778803) | Verastem, Inc. | 2013-02-26 |
| A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable (NCT01739218) | Hoffmann-La Roche | 2013-02-01 |
| BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer (NCT01669798) | AA Secord | 2013-02-01 |
| Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT01767675) | Memorial Sloan Kettering Cancer Center | 2013-01-08 |
| Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study (NCT01705288) | Masonic Cancer Center, University of Minnesota | 2013-01-01 |
| Accelerating Gastrointestinal Recovery (NCT01704651) | Jamie N. Bakkum-Gamez | 2013-01-01 |
| Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma (NCT01824615) | Cathay General Hospital | 2013-01-01 |
| Cabazitaxel in Platinum Refractory Ovarian Cancer (NCT01747239) | Vejle Hospital | 2013-01-01 |
| A Pilot Test for Newly Developed Synoptic Operative Template for Ovarian Cancer (SOTOC): National Cancer Center - Peritoneal Carcinomatosis Index (NCT01823731) | National Cancer Center, Korea | 2013-01-01 |
| A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus (NCT01787656) | University of South Alabama | 2013-01-01 |
| Shanghai Ovarian Cancer and Family Care Project (NCT06118307) | Shanghai First Maternity and Infant Hospital | 2013-01-01 |
| PDL1 in Ovarian High Grade Serous Carcinoma (NCT04507191) | Port Said University hospital | 2012-12-01 |
| 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant (NCT01766622) | National Institutes of Health Clinical Center (CC) | 2012-11-30 |
| Strength Training Study for Survivors of Breast and Gynecologic Cancer (NCT01709175) | Nova Scotia Health Authority | 2012-11-01 |
| Oxford Ovarian Cancer Predict Chemotherapy Response 01 (NCT01770535) | University of Oxford | 2012-11-01 |
| The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study (NCT01743547) | Northwestern University | 2012-11-01 |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status (NCT01690598) | Vejle Hospital | 2012-11-01 |
| Elecsys HE4 Chinese Reference Value Study (NCT01738269) | Chinese PLA General Hospital | 2012-11-01 |
| Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) (NCT01684878) | Hoffmann-La Roche | 2012-10-22 |
| BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients (NCT01624493) | Hoosier Cancer Research Network | 2012-10-01 |
| Sentinel Node Detection in Clinical Early Stage Ovarian Cancer (NCT01734746) | Maastricht University Medical Center | 2012-10-01 |
| A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer (NCT01715168) | Azaya Therapeutics, Inc. | 2012-10-01 |
| Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer (NCT01744821) | Northwestern University | 2012-10-01 |
| Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum (NCT01705158) | ARCAGY/ GINECO GROUP | 2012-10-01 |
| Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab (NCT01706120) | National Cancer Institute, Naples | 2012-10-01 |
| Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project (NCT01691144) | University of Oslo | 2012-09-01 |
| Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer (NCT01623349) | Dana-Farber Cancer Institute | 2012-09-01 |
| A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer (NCT01610206) | Linda R Duska | 2012-09-01 |
| SGI-110 in Combination With Carboplatin in Ovarian Cancer (NCT01696032) | Astex Pharmaceuticals, Inc. | 2012-09-01 |
| Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer (NCT01679483) | Asan Medical Center | 2012-09-01 |
| Diffusion-weighted Imaging Study in Cancer of the Ovary (NCT01505829) | Institute of Cancer Research, United Kingdom | 2012-08-01 |
| Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer (NCT01661868) | Dana-Farber Cancer Institute | 2012-08-01 |
| A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy (NCT01685255) | Incyte Corporation | 2012-08-01 |
| Comparison to Psychological, Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics Tests (NCT03889171) | University Hospital, Montpellier | 2012-08-01 |
| Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (NCT01402271) | European Organisation for Research and Treatment of Cancer - EORTC | 2012-07-01 |
| Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy (NCT01601548) | Masonic Cancer Center, University of Minnesota | 2012-07-01 |
| Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) (NCT01584115) | Instituto de Investigação em Imunologia | 2012-07-01 |
| Blood Test for Ovarian Cancer Associated Auto Antibodies (NCT01334437) | Eventus Diagnostics Ltd | 2012-06-01 |
| Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer. (NCT02910622) | University Hospital, Limoges | 2012-06-01 |
| Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer (NCT01583322) | ARCAGY/ GINECO GROUP | 2012-06-01 |
| Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis (NCT01441089) | National Cancer Institute (NCI) | 2012-05-21 |
| CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer (NCT01583686) | National Cancer Institute (NCI) | 2012-05-04 |
| Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) (NCT01600573) | JSehouli | 2012-05-01 |
| Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer (NCT01591772) | Memorial Sloan Kettering Cancer Center | 2012-04-24 |
| Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors (NCT01572467) | Children's Oncology Group | 2012-04-01 |